Análisis Argos
CI
CIBarata · ojo al riesgo
Cigna Corporation · Healthcare
US$ 301.06
precio al 2026-07-28
Valor justo Argos*
US$ 540–597
vs. su valor justo
50% por debajo
Score Argos
69/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 10.3% al año — menos de lo que viene demostrando (8.7%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Las ganancias crecieron 73% el último año.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
VALOR4/6FUTURO4/6PASADO4/6SALUD2/6DIVIDENDO5/6
El Iris de calidad
VALOR4/6FUTURO4/6PASADO4/6SALUD2/6DIVIDENDO5/6
ValorCotiza por debajo de su valor justo
FuturoIngresos creciendo con fuerza
PasadoFundamentales sólidos y sostenidos
SaludBalance razonable
DividendoDevuelve capital al accionista
Score Argos69de 100Barata · ojo al riesgo
Ingresos11%
US$ 275 B
Margen operativo13%
3.3%
Flujo de caja libre6%
US$ 8.4 B
Deuda neta
US$ 23.8 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 79.6B
P/E13.4x
EV/EBITDA8.8x
FCF yield10.5%
ROIC11.5%
Margen operativo3.3%
Crecim. ingresos+11.3%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

seekingalpha.com · 11 jul
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.1%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
zacks.com · 7 jul
Here's Why Cigna (CI) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
prnewswire.com · 7 jul
The Cigna Group's Second Quarter 2026 Earnings Release Details
BLOOMFIELD, Conn., July 7, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its second quarter 2026 financial results on Thursday, July 30, 2026, and will host a conference call the same day.
zacks.com · 2 jul
Cigna Brings AI to Specialty Pharmacy With Pharmacy Forward
Cigna's Evernorth launched AI-powered Pharmacy Forward to speed up specialty prescriptions, cut delays and boost efficiency with a $100M investment.
prnewswire.com · 1 jul
Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
New program introduces AI-enabled capabilities to personalize support, streamline prescription processing, and help patients start and stay on therapy with greater ease and confidence BLOOMFIELD, Conn., July 1, 2026 /PRNewswire/ -- As specialty care becomes more complex, patients need faster, more connected, and personalized support.
zacks.com · 25 jun
Can Cigna's Expansion Beyond Health Insurance Fuel Long-Term Growth?
CI is evolving beyond traditional insurance, using AI, specialty pharmacy and healthcare services to drive growth and sharpen its business focus.
prnewswire.com · 25 jun
The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities
New "Courage in Service" grant builds on company's long-standing support for military and veteran communities. BLOOMFIELD, Conn.
zacks.com · 24 jun
Here's Why Cigna (CI) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.